A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510923-20-00

Acronym

MK-6024-017

Enrollment

Registered

2024-08-05

Start date

2024-09-16

Completion date

Unknown

Last updated

2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Dysfunction-Associated Steatohepatitis

Brief summary

Change from baseline in liver fat content (LFC) at week 28, Percentage of participants who experienced an adverse event (AE), Percentage of participants discontinuing study medication due to an AE

Detailed description

Change from baseline in iron-corrected T1 (cT1) at week 28, Change from baseline in enhanced liver fibrosis (ELF) score at week 28, Change from baseline in propeptide of type III collagen (Pro-C3) at week 28, Change from baseline in fibrosis-4 index (FIB-4) at week 28, Change from baseline in liver stiffness measurement (LSM) assessed by vibration-controlled transient elastography (VCTE) at week 28, Percent change from baseline in body weight at week 28

Interventions

DRUGefinopegdutide

DRUGPlacebo to MK-6024

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in liver fat content (LFC) at week 28, Percentage of participants who experienced an adverse event (AE), Percentage of participants discontinuing study medication due to an AE	—

Secondary

Measure	Time frame
Change from baseline in iron-corrected T1 (cT1) at week 28, Change from baseline in enhanced liver fibrosis (ELF) score at week 28, Change from baseline in propeptide of type III collagen (Pro-C3) at week 28, Change from baseline in fibrosis-4 index (FIB-4) at week 28, Change from baseline in liver stiffness measurement (LSM) assessed by vibration-controlled transient elastography (VCTE) at week 28, Percent change from baseline in body weight at week 28	—

Measure

Time frame

—

Countries

France, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026